Patents by Inventor Kenichi Teramoto

Kenichi Teramoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-aqueous electrolyte magnesium secondary battery
    Patent number: 10998574
    Abstract: This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO2CF3)2]? as an anion, and Mg2+ and/or an organic onium cation as a cation.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: May 4, 2021
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Keigo Kubota, Kenichi Teramoto, Rie Ooyabu, Hajime Matsumoto
  • NON-AQUEOUS ELECTROLYTE MAGNESIUM SECONDARY BATTERY
    Publication number: 20170294675
    Abstract: This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO2CF3)2]? as an anion, and Mg2+ and/or an organic onium cation as a cation.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 12, 2017
    Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Keigo KUBOTA, Kenichi TERAMOTO, Rie OOYABU, Hajime MATSUMOTO
  • Method for inhibiting allograft rejection using photoactivatable nucleotides or nucleosides
    Patent number: 5200400
    Abstract: Method for inhibiting acute rejection of a transplanted organ or tissue by a recipient mammal that includes the steps of administering to the mammal a compound which causes selective sensitization of the alloreactive lymphocytes of the transplant recipient that are involved in the rejection process to a toxin; and exposing the mammal to the toxin to selectively destroy the sensitized alloreactive lymphocytes to a greater extent than non-sensitized cells of the mammal. This method induces donor specific tolerance in the transplant recipient, i.e., acceptance of the new organ or tissue without suppression of the rest of the recipient's normal immune system.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: April 6, 1993
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Kenichi Teramoto, Melvin E. Clouse